SCHEMBL31158539

SCHEMBL31158539

Cn1c(Cl)cc2c(Br)cccc2c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 3/20 0.37
▸ BTK Q06187 3/20 0.37
▸ PDE3B Q13370 1/20 0.36
▸ PDE3A Q14432 1/20 0.36
▸ PARP1 P09874 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA2B P29275 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ CYP19A1 P11511 1/20 0.34
▸ NQO2 P16083 1/20 0.34
▸ PDE7A Q13946 1/20 0.34
▸ DPP4 P27487 1/20 0.34
▸ BRD1 O95696 1/20 0.34
▸ TAF1 P21675 1/20 0.34
▸ BRPF1 P55201 1/20 0.34
▸ ESR1 P03372 1/20 0.33
▸ ESRRA P11474 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27306599 0.76 DDR1 (0.32) ESR1ESR2MAPT
SCHEMBL31158518 0.76 BRD4 (0.47) MAPT
SCHEMBL30564385 0.75 PGR (0.32) —
SCHEMBL31158480 0.74 CYP1A2 (0.41) ADORA3ADORA2AADORA2BADORA1CYP19A1
SCHEMBL15228958 0.73 ALDH1A1 (0.41) JAK2BTKPDE7AMAPT
SCHEMBL11454047 0.73 GAA (0.51) ADORA3ADORA2AADORA2BADORA1MAPT
SCHEMBL15519326 0.69 GAA (0.56) PARP1MAPT
SCHEMBL30529453 0.69 GAA (0.56) PARP1MAPT
SCHEMBL30480838 0.69 KDM4E (0.50) JAK2BTKNQO2BRD1TAF1
SCHEMBL26547562 0.69 KDM4E (0.50) JAK2BTKNQO2BRD1TAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125346-A1 Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease BEONE MEDICINES I GMBH (CH) 2026-05-07 — — US disclosed
EP-4709711-A1 ISOQUINOLINONE DERIVATIVES AND 4H-QUINOLIZINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE Beone Medicines I GmbH (CH) 2026-03-18 — — EP disclosed
WO-2024230803-A1 ISOQUINOLINONE DERIVATIVES AND 4H-QUINOLIZINONE DERIVATIVES AND PHARMARCEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE BEIGENE, LTD. (GB) 2024-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125346-A1 Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease NR3C1, NR3C2, PIK3R4 JAK2 558/4885BTK 641/4885PDE3B 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback